Subvenite Tablet
NDC Package 69102-301-01
Package Information
Subvenite (lamotrigine) tablets is adjunctive TherapySUBVENITE is indicated as adjunctive therapy for the following seizure types in patients aged 2 years and older:partial-onset seizures.primary generalized tonic-clonic (PGTC) seizures.generalized seizures of Lennox-Gastaut syndrome.MonotherapySUBVENITE is indicated for conversion to monotherapy in adults (aged 16 years and older) with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED).Safety and effectiveness of SUBVENITE have not been established (1) as initial monotherapy; (2) for conversion to monotherapy from AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate; or (3) for simultaneous conversion to monotherapy from 2 or more concomitant AEDs. This formulation utilizes a tablet delivery system. Marketed by Owp Pharmaceuticals, Inc., this product is identified by NDC 69102-301 and is authorized under FDA application ANDA078947.
Identification & Billing
- RxCUI: 198427 - lamoTRIgine 100 MG Oral Tablet
- RxCUI: 198427 - lamotrigine 100 MG Oral Tablet
- RxCUI: 198428 - lamoTRIgine 150 MG Oral Tablet
- RxCUI: 198428 - lamotrigine 150 MG Oral Tablet
- RxCUI: 198429 - lamoTRIgine 200 MG Oral Tablet
Clinical Specifications
- Anti-epileptic Agent - [EPC] (Established Pharmacologic Class)
- Decreased Central Nervous System Disorganized Electrical Activity - [PE] (Physiologic Effect)
- Dihydrofolate Reductase Inhibitors - [MoA] (Mechanism of Action)
- Mood Stabilizer - [EPC] (Established Pharmacologic Class)
- Organic Cation Transporter 2 Inhibitors - [MoA] (Mechanism of Action)
Regulatory & Marketing
Hierarchy Structure
- 69102 - Owp Pharmaceuticals, Inc.
- 69102-301 - Subvenite
- 69102-301-01 - 100 TABLET in 1 BOTTLE
- 69102-301 - Subvenite
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (69102-301). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 69102-301-01 identifies a specific commercial package of 100 tablet in 1 bottle of Subvenite, a human prescription drug labeled by Owp Pharmaceuticals, Inc.. This tablet is formulated for oral use and contains lamotrigine as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Owp Pharmaceuticals, Inc. on March 10, 2018. The current certification is valid through December 31, 2027.
How is this Owp Pharmaceuticals, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 69102030101. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.